Trial Profile
A 1 month, open-label inpatient, randomized cross-over trial assessing the impact of dry powder inhaled insulin (Exubera) on 24-hour glycemic control compared to insulin glargine (Lantus) in patients with type 2 diabetes mellitus who are poorly controlled on a combination of two oral agents
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Aug 2009
Price :
$35
*
At a glance
- Drugs Insulin (Primary) ; Insulin glargine
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 01 Jul 2009 Results published in Diabetes, Obesity and Metabolism.
- 17 Nov 2006 New trial record.